Press release
Hyperphosphatemia Market Outlook 2034 - Clinical Trials, Market Size, Medication, Prevalence, Companies by DelveInsight
Hyperphosphatemia market in the 7MM was valued at approximately USD 4 billion in 2023 and is projected to grow, driven by rising chronic kidney disease (CKD) prevalence and an expanding patient pool.Hyperphosphatemia Market Summary
Hyperphosphatemia, defined as elevated serum phosphate levels (>4.5 mg/100 mL), commonly affects CKD patients due to impaired renal function. The United States accounted for nearly 50% of total cases in 2023 and represents the largest market, followed by the EU4, the United Kingdom, and Japan. Hyperphosphatemia market growth is expected from improved uptake of existing drugs, increased awareness, and the anticipated launch of advanced therapies, including one-time gene treatments. In 2023, the U.S. had about 600,000 end-stage renal disease (ESRD) patients on dialysis, a number expected to rise. Approved phosphate binders include KIKLIN, AURYXIA/RIONA, and VELPHORO/P-TOL . Recently, XPHOZAH gained FDA approval for dialysis patients intolerant to binders, while Oxylanthanum Carbonate (OLC) is emerging as a promising therapy.
DelveInsight's "Hyperphosphatemia Market Insights, Epidemiology, and Market Forecast-2034" report provides a comprehensive evaluation of Hyperphosphatemia, encompassing historical trends and projected epidemiology, along with market dynamics across the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. The analysis details current therapeutic practices, emerging treatment options, market share distribution among available therapies, and the estimated market size for Hyperphosphatemia from 2020 to 2034 across seven major markets. Additionally, the report examines prevailing treatment algorithms, key market drivers and barriers, and existing unmet clinical needs, thereby identifying strategic opportunities and assessing the growth potential of the Hyperphosphatemia market.
The $4B Hyperphosphatemia market is evolving fast with new therapies like XPHOZAH & OLC. Get DelveInsight's latest Hyperphosphatemia Market Forecast (2020-2034) for growth trends, pipeline insights & strategic opportunities @ Hyperphosphatemia Market Outlook [https://www.delveinsight.com/report-store/hyperphosphatemia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Some facts of the Hyperphosphatemia Market Report are:
* According to DelveInsight, The hyperphosphatemia market in the 7MM was valued at approximately USD 4 billion in 2023.
* Leading Hyperphosphatemia companies working in the market are Phosphate Therapeutics, Bayer, Shire, Kyowa Kirin Co Ltd, Shanghai Alebund Pharmaceuticals Limited, Ardelyx, Kissei Pharmaceutical Co. Ltd., Taisho Pharmaceutical Co. Ltd., Sanofi, Chugai Pharmaceutical, Astellas Pharma Inc., Alebund Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, KDL Inc., Denver Nephrologists, CM&D Pharma Limited, Daiichi Sankyo and others.
* Key Hyperphosphatemia Therapies are Oxylanthanum Carbonate (OLC), KIKLIN, VELPHORO/P-TAL, AURYXIA/ RIONA, and many others.
* In June 2025, Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, announced that the U.S. Food and Drug Administration (FDA) has issued a CRL for its New Drug Application (NDA) for oxylanthanum carbonate (OLC) to treat hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis.
* In June 2025, Alebund Pharmaceuticals ("Alebund" or the "Company"), an integrated biopharmaceutical company focusing on developing innovative therapies for renal diseases and related chronic conditions, announced the database lock was achieved on June 16, 2025 for the pivotal phase 3 study of its investigational drug AP301, a new generation of oral iron-based phosphate binder, in dialysis patients with hyperphosphatemia. The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in serum phosphorus control with AP301. The safety profile of AP301 is favorable and consistent with previous studies.
* In February 2025, Ardelyx Gains Approval for Tenapanor to Treat hyperphosphatemia. Ardelyx has announced that China's National Medical Products Administration (NMPA) has approved tenapanor for controlling serum phosphorus levels in dialysis patients with chronic kidney disease (CKD).
Hyperphosphatemia Overview
Hyperphosphatemia is a metabolic disorder characterized by abnormally elevated serum phosphate levels, typically defined as concentrations exceeding 4.5 mg/dL. It is most commonly observed in patients with chronic kidney disease (CKD), particularly those in advanced stages or undergoing dialysis, due to the kidneys' reduced ability to excrete phosphate efficiently. The condition is clinically significant because persistently high phosphate levels can lead to vascular calcification, cardiovascular complications, secondary hyperparathyroidism, and bone-mineral disorders, collectively increasing morbidity and mortality in CKD patients.
The prevalence of hyperphosphatemia closely parallels the rising global burden of CKD and end-stage renal disease (ESRD). In 2023, the United States accounted for nearly half of the total hyperphosphatemia cases across the seven major markets (7MM), highlighting its substantial clinical and economic impact. Current management strategies primarily involve dietary phosphate restriction, dialysis optimization, and the use of phosphate binders, which are classified into calcium-based and non-calcium-based agents. Despite their effectiveness, treatment adherence remains a challenge due to pill burden and gastrointestinal side effects.
Ongoing research focuses on novel therapies such as iron-based binders, new molecular agents, and gene therapy approaches to address unmet needs. Rising awareness, better diagnostics, and emerging treatment options are expected to reshape the market outlook.
Access in-depth insights on Hyperphosphatemia key players, therapies, market drivers, barriers, and opportunities across the 7MM @ Hyperphosphatemia Clinical Trials and FDA Approvals [https://www.delveinsight.com/sample-request/hyperphosphatemia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Hyperphosphatemia Market Outlook
In the hyperphosphatemia landscape, companies such as Unicycive Therapeutics are advancing lead candidates through various stages of clinical development to expand treatment options. The 7MM market is largely driven by the use of phosphate binders (both calcium-based and calcium-free) along with off-label therapies. In 2023, the United States accounted for the largest share, with a market size of approximately USD 2,400 million. Within the EU4 and the UK, Germany contributed the most, with around USD 150 million.
Hyperphosphatemia Market Drivers
* Rising CKD and ESRD prevalence: Growing patient pool, particularly those on dialysis, increases hyperphosphatemia incidence.
* Improved diagnostic rates: Enhanced awareness and early detection of CKD-associated complications drive treatment demand.
* Pipeline innovations: Emerging therapies (e.g., Oxylanthanum Carbonate, novel gene therapies) expected to expand treatment landscape.
* Regulatory approvals: New drug approvals (e.g., XPHOZAH, 2023 FDA approval) strengthen treatment options.
* Shift toward non-calcium-based binders: Preference for safer, effective alternatives fuels adoption.
* Rising awareness among physicians and patients: Better disease education promotes compliance and treatment uptake.
Hyperphosphatemia Market Barriers
* Treatment compliance issues: Phosphate binders often require multiple daily doses, impacting adherence.
* Adverse effects of therapies: Gastrointestinal intolerance and other side effects limit long-term use.
* Cost constraints: High pricing of newer therapies poses affordability challenges, especially in emerging markets.
* Limited novel mechanisms of action: Market still dominated by phosphate binders with incremental innovations.
* Slow penetration of advanced therapies: Gene therapies and novel drugs face long regulatory and clinical timelines.
* Unmet needs in refractory patients: Some patients remain unresponsive or intolerant to existing binders.
Interested to know how the emerging diagnostic approaches will be contributing in increased Hyperphosphatemia diagnosed prevalence pool? Download report @ Hyperphosphatemia Patient Pool [https://www.delveinsight.com/report-store/hyperphosphatemia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Hyperphosphatemia Epidemiology
The Hyperphosphatemia epidemiology section provides insights into the historical and current Hyperphosphatemia patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. In 2023, the United States recorded the highest prevalence of hyperphosphatemia in the 7MM, with ~500,000 cases, alongside ~2.4 million CKD stage 3-5 patients. Japan ranked second, contributing ~300,000 cases, while Germany led among the EU4 and the UK with ~56,000 cases.
Hyperphosphatemia Epidemiology Segmentation:
* Total Prevalent Cases of Chronic Kidney Disease (CKD)
* Total Diagnosed Prevalent Cases of CKD
* Stage-specific Distribution of CKD
* Total Prevalent Cases of End-Stage Renal Disease (ESRD)
* Number of ESRD Patients Undergoing Dialysis
* Total Prevalent Cases of Hyperphosphatemia
Hyperphosphatemia Drugs Uptake
VELPHORO/P-TOL (Fresenius Medical Care/Vifor Pharma)
Approved in the US (2013) and Europe (2014), VELPHORO (sucroferric oxyhydroxide) is widely marketed, including Japan (as P-TOL since 2018 through Kissei). It is available in over 30 countries, benefitting more than 100,000 patients annually.
KIKLIN (Astellas Pharma)
An amine-functional polymer (bixalomer) approved in 2012 for CKD patients on dialysis, with its indication expanded in 2016 to include all CKD-related hyperphosphatemia. It lowers phosphate absorption by binding in the GI tract.
Oxylanthanum Carbonate (OLC, Unicycive Therapeutics)
A novel nanoparticle-based phosphate binder designed to reduce pill burden by enabling smaller, easier-to-swallow tablets. Phase II trials have shown strong safety and tolerability, with FDA submission planned via the 505(b)(2) pathway.
Discover how VELPHORO, KIKLIN, and OLC are shaping the Hyperphosphatemia market. Get insights on drug uptake trends, pipeline shifts, and growth opportunities.
Download your sample report now! @ Hyperphosphatemia Medication and Companies [https://www.delveinsight.com/sample-request/hyperphosphatemia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Hyperphosphatemia Therapeutics Assessment
Major key companies are working proactively in the Hyperphosphatemia Therapeutics market to develop novel therapies which will drive the Hyperphosphatemia treatment markets in the upcoming years are Phosphate Therapeutics, Bayer, Shire, Kyowa Kirin Co Ltd, Shanghai Alebund Pharmaceuticals Limited, Ardelyx, Kissei Pharmaceutical Co. Ltd., Taisho Pharmaceutical Co. Ltd., Sanofi, Chugai Pharmaceutical, Astellas Pharma Inc., Alebund Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, KDL Inc., Denver Nephrologists, CM&D Pharma Limited, Daiichi Sankyo and others.
Discover how leading pharma innovators are reshaping the Hyperphosphatemia treatment algorithm with novel therapies? Download sample report @ Hyperphosphatemia Clinical Trials and FDA Approvals [https://www.delveinsight.com/sample-request/hyperphosphatemia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Hyperphosphatemia Report Key Insights
1. Hyperphosphatemia Patient Population
2. Hyperphosphatemia Market Size and Trends
3. Key Cross Competition in the Hyperphosphatemia Market
4. Hyperphosphatemia Market Dynamics (Key Drivers and Barriers)
5. Hyperphosphatemia Market Opportunities
6. Hyperphosphatemia Therapeutic Approaches
7. Hyperphosphatemia Pipeline Analysis
8. Hyperphosphatemia Current Treatment Practices/Algorithm
9. Impact of Emerging Therapies on the Hyperphosphatemia Market
Table of Contents
1. Key Insights
2. Executive Summary
3. Hyperphosphatemia Competitive Intelligence Analysis
4. Hyperphosphatemia Market Overview at a Glance
5. Hyperphosphatemia Disease Background and Overview
6. Hyperphosphatemia Patient Journey
7. Hyperphosphatemia Epidemiology and Patient Population
8. Hyperphosphatemia Treatment Algorithm, Current Treatment, and Medical Practices
9. Hyperphosphatemia Unmet Needs
10. Key Endpoints of Hyperphosphatemia Treatment
11. Hyperphosphatemia Marketed Products
12. Hyperphosphatemia Emerging Therapies
13. Hyperphosphatemia Seven Major Market Analysis
14. Attribute Analysis
15. Hyperphosphatemia Market Outlook (7 major markets)
16. Hyperphosphatemia Access and Reimbursement Overview
17. KOL Views on the Hyperphosphatemia Market
18. Hyperphosphatemia Market Drivers
19. Hyperphosphatemia Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=hyperphosphatemia-market-outlook-2034-clinical-trials-market-size-medication-prevalence-companies-by-delveinsight]
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/competitive-intelligence-services
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hyperphosphatemia Market Outlook 2034 - Clinical Trials, Market Size, Medication, Prevalence, Companies by DelveInsight here
News-ID: 4149737 • Views: …
More Releases from ABNewswire

Top Medicare Insurance in Greenville, SC, Broker Shares Insights on Market Shift …
True Heart Insurance reports significant changes in the regional insurance marketplace as new carriers expand into Upstate South Carolina counties. These developments are creating both opportunities and challenges for residents seeking coverage options in an increasingly dynamic environment.
The agency, which began serving both English and Hispanic communities in 2013, has established a reputation for personalized service in policy selection and enrollment. Through consistent growth driven by strategic marketing and strong…

Hamptons Real Estate Lawyer Peter Zinkovetsky Guides Buyers and Sellers Through …
Navigating the competitive and often high-stakes Hamptons real estate market requires careful planning and legal oversight. Hamptons real estate lawyer Peter Zinkovetsky (https://www.avenuelawfirm.com/hamptons-real-estate-lawyer/), founder and Managing Partner of Avenue Law Firm, offers legal support to help clients in East Hampton, Southampton, and surrounding areas protect their property interests from offer to closing.
Whether purchasing a summer retreat or selling a longtime family home, individuals need a Hamptons real estate lawyer who…

Brooklyn Slip and Fall Lawyer Samantha Kucher Shares Insight on Average Payouts …
Brooklyn slip and fall lawyer Samantha Kucher, Esq. (https://www.rrklawgroup.com/average-payout-for-slip-and-fall-injury/) offers a practical and in-depth look at the potential value of a slip and fall injury claim in a recent article published by Kucher Law Group. The article, titled "Average Payout For Slip and Fall Injury", provides a clear explanation of how injury severity, fault, and financial loss all shape the outcome of a personal injury case.
Slip and fall accidents are…

EverClear Pools & Spas Sets New Standards for Vinyl Pool Repair Services in New …
Pools are often the centerpiece of summer fun, but when wear and tear affect their appearance and performance, homeowners look for trusted professionals who can restore them to peak condition. EverClear Pools & Spas, a leader in pool care and maintenance, continues to make waves as the go-to vinyl pool repair company in the region, offering high-quality solutions designed to extend the life and beauty of every pool.
Meeting the Demand…
More Releases for Hyperphosphatemia
Sustainable Growth Of Hyperphosphatemia Treatment Market Amid Rising Chronic Dis …
Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.
What Will the Hyperphosphatemia Treatment Industry Market Size Be by 2025?
The market for hyperphosphatemia treatment has expanded quickly in recent years. Its size is set to increase from $4.56 billion in 2024 to $5.13 billion in 2025, with a compound annual growth rate (CAGR) of 12.4%. The extension during the historical period is…
Key Influencer in the Hyperphosphatemia Treatment Market 2025: Sustainable Growt …
What industry-specific factors are fueling the growth of the hyperphosphatemia treatment market?
The rise in chronic illnesses among patients is boosting the hyperphosphatemia treatment market. Conditions like cardiovascular and kidney diseases, chronic respiratory conditions, hyperparathyroidism, diabetes, and cancer all fall under the category of chronic diseases, which are non-communicable and demand long-term management. For instance, the World Health Organization reported in September 2023 that 74% of the 41 million global deaths…
Hyperphosphatemia Pipeline Insight Report 2024
(Albany, United States) As per DelveInsight's assessment, globally, the Hyperphosphatemia Pipeline constitutes 15+ key companies continuously working towards developing 15+ Hyperphosphatemia Pipeline treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.
In the Hyperphosphatemia Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Hyperphosphatemia NDA approvals (if any), and product development activities comprising…
Hyperphosphatemia Drugs Market to Witness Robust Expansion by 2029
The Hyperphosphatemia Drugs Market size is expected to grow at an annual average of CAGR 2% during the forecast period (2023-2029). Hyperphosphatemia is characterized by an elevated level of phosphate in the blood as a result of increased intake of phosphate, migration of phosphate out of the cells, and decreased excretion of phosphate. Hyperphosphatemia is frequently found in people who suffer from chronic kidney diseases, diabetic uncontrolled diabetes, and low…
Hyperphosphatemia- Market Insight, Epidemiology and Market Forecast -2030
Hyperphosphatemia Market research report is the new statistical data source added by Infinity Business Insights.
Hyperphosphatemia is a condition in which your blood contains a lot of phosphate (or phosphorus). Phosphate is an electrolyte, a chemically charged compound containing the mineral phosphorus. Phosphate is required by your body to strengthen your bones and teeth, create energy, and construct cell membranes. Phosphate, on the other hand, in excess can cause bone…
Hyperphosphatemia Drugs Market Opportunity Analysis, 2018 - 2026
Hyperphosphatemia is a condition caused due to high level of phosphate or phosphorous in the blood. Phosphate is a chemical found in body and contain mineral called phosphorous. Phosphorus mineral is very important for the development of teeth and bones and also convert food into energy for body. Phosphate is mainly found in the teeth, bones, inside the cells, and in very smaller amounts in the blood. Kidney functions for…